Also listed on Vertical Bio AG, an earlier holder on the record. The recorded assignments below show how it moved.
Term ends Feb 5, 2027 · High confidence
20-year base term ends Feb 5, 2027
Held by Pierre Fabre Médicament
Filed Nov 4, 2011 as application 13/373,101 · Granted May 20, 2014
Base term, 20 years from filing
Today
2007
2027
Clock starts
Feb 5, 2007
Feb 5, 2007
Term ends
Feb 5, 2027
Feb 5, 2027
Granted
May 20, 2014
May 20, 2014
base term
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
None
Terminal disclaimer
No disclaimer on this record.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
3
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. All three maintenance fees are recorded paid; no more fees are due. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Feb 5, 2007, when application PCT/EP2007/051066, the earliest non-provisional in its chain, was filed (this one was filed Nov 4, 2011) | Feb 5, 2027 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Feb 5, 2027 | High confidence |
This family
| US 8,388,958 | In force Jul 2029 | Jul 2029 |
| US 8,729,043 | this patent Feb 2027 | Feb 2027 |
2 of 3 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Nov 9, 2021 Reel 58062, frame 671 | Comoglio, Paolo Maria; Vigna, Elisa; Giordano, Silvia | Metheresis Translational Research S.A. | Assignment of Assignor's Interest |
| Nov 9, 2021 Reel 58063, frame 631 | Metheresis Translational Reserach S.A. | Metis Precision Medicine SB S.R.L. | Assignment of Assignor's Interest |
| Nov 9, 2021 Reel 58064, frame 112 | Metis Precision Medicine SB S.R.L. | Vertical Bio AG | Assignment of Assignor's Interest |
| Oct 24, 2024 Reel 69000, frame 533 | Vertical Bio AG | Pierre Fabre Médicament | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
Feb 2027
Term ends Feb 5, 2027. No further fees fall due before then
Citations
11
later US patents cite this one
That is above the median of utility patents granted in 2014 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.